Liver Care

INTERVENTIONAL: Liver Care

A Complete Suite of Solutions to Enable Excellence in Liver Care Interventions with CBCT

Liver cancer accounts for approximately 64%(Ref. 1) of all Interventional Oncology procedures and CBCT is proven to improve the feasibility, effectiveness, and safety of challenging interventions.(Ref. 2) GE's comprehensive liver care solutions are engineered to enable physicians to access the full-potential of CBCT images within their daily practice by removing the most common barriers.


From acquisition, to application, through final assessment, GE's complete liver care portfolio supports excellence in endovascular and percutaneous procedures by enabling you to: 

  • Obtain high-quality CBCT acquisitions with Discovery IGS 7(Ref. 3)  (wide bore gantry, 41 cm2 detector).
  • Compensate for involuntary respiratory motion artifacts that threaten CBCT quality with Motion Freeze(Ref. 4). 
  • Employ precise surgical planning and embolization guidance with Liver ASSIST(Ref. 5). 
  • INTERACT Active Tracker(Ref. 6) enables fusion between U/S(Ref. 7) and CBCT as  well as other pre-operative images.
  • Access dedicated ablation planning software with Needle ASSIST(Ref. 8) in the angio suite.
  • The combined capabilities of GE's Liver Care portfolio equip clinical teams to confidently access and leverage CBCT in even the most challenging procedures for endovascular and needle-based treatments.
 

Fast Facts

  • info
    64%1 of IO procedures are targeted to liver. GE solutions address endovascular and ablative care with diversified solutions.
  • diagnosis

    In up to 81% 2 of HCC lesions treated by TACE, CBCT provides 3D information that aids in:
    - lesion detection
    - catheter navigation
    - assessment of technical success of treatment delivery

  • global
    GE Liver Care portfolio allows 3D imaging to potentially more than 95% of the world's adult population (aged 15 to 100)9 thanks to the Discovery IGS 7, one of the widest bore on the market today.
  • info
    Physicians estimate that up to 40% of CBCT acquisitions are unusable due to involuntary respiratory motion artifacts.10 Thanks to Motion Freeze refine and increase small contrasted structures in CBCT images recovering vascular CBCT images that would have been discarded.
  • statistics
    Liver ASSIST through FlightPlan for Liver, improves the sensitivity of tumor-feeding vessels identification versus the use of either DSA or CBCT alone, by up to 97 %.11,12,13
  • diagnosis
    Liver ASSIST, through FlightPlan for Liver5 is the only software solution able to demonstrate ~68%complete tumor response rate (36% with DSA alone)14
  • ultrasound
    Facilitates access to ultrasound fusion7 Facilitates access to ultrasound fusion for needle based procedures and leverage radiation-free modality with INTERACT Active Tracker
   
Contact Us
1. Kwan, S. W., Kerlan, R. K., & Sunshine, J. H. (2010). Utilization of Interventional Oncology Treatments in the United States. Journal of Vascular and Interventional Radiology: JVIR, 21(7), 1054–1060. http://doi.org/10.1016/j.jvir.2010.02.028

2. http://pubs.rsna.org/doi/pdf/10.1148/radiol.14131925

3. Discovery IGS 7 cannot be placed on the market or put into service until it has been made to comply with all required regulatory authorizations including the Medical Device Directive requirements for CE marking. Discovery IGS 7 and products mentioned in this material cannot be marketed in countries where market authorization is required and nor yet obtained. Refer to your sales representatives

4. Motion Freeze cannot be marketed in countries where market authorization is required and not yet obtained. Refer to your sales representative. The improvement related to Motion Freeze depends on the acquisition conditions, table position, patient, type of motion, anatomical location and clinical practice. Motion Freeze is an optional feature of 3DXR (part of GE vascular systems IGS 5, IGS 6 and IGS 7 or IGS 7OR). 3DXR cannot be placed on the market or put into service until it has been made to comply with all required regulatory authorizations including the Medical Device Directive requirements for CE marking. Motion Freeze cannot be marketed in countries where market authorization is required and not yet obtained. Refer to your sales representative for CE marking

5. Liver ASSIST solution includes Hepatic VCAR, FlightPlan For Liver and Integrated Registration which can be use independently and requires AW workstation with Volume Viewer, Volume Viewer Interventional. These applications are sold separately.

6. INTERACT Active Tracker is an optional feature of 3DXR (part of GE vascular systems IGS 5, IGS 6 and IGS 7 or IGS 7OR). This feature supports only one ‘Active Tracker’ type: the OmniTRAXTM Active Patient Tracker of CIVCOTM. 3DXR cannot be placed on the market or put into service until it has been made to comply with all required regulatory authorizations including the Medical Device Directive requirements for CE marking. INTERACT Active Tracker cannot be marketed in countries where market authorization is required and not yet obtained. Refer to your sales representative

7. Requires availability of a LOGIQ E9 system with XD clear (sold separately)

8. Needle ASSIST solutions includes TrackVision 2, Stereo 3D and requires AW workstation with Volume Viewer, Volume Viewer Interventional. These applications are sold separately

9. Established from health Organization databases publicly available. World’s Health Organization data “Global Database on Body Mass Index” and World’s Health Organization:“Obesity and overweight Fact sheet N°311 Updated January 2015” and “CDC/NCHS 2007-2008 National Health and Nutrition examination survey and 2007 – 2009 Canadian Health measures survey

10. Based on the quantitative assessment of 6 recognized Interventional Radiologists specialized in the field of Interventional Oncology, using various intervention angiography systems from different vendors

11. Computed Analysis of Three-Dimensional Cone-Beam Computed Tomography Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumor: A Pilot Study – Deschamps et al. Cardiovasc Intervent Radiol. 2010

12. Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography – Minami et al. Liver Cancer. 2014

13. Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Iwazawa et al. European Journal of Radiology. 2013. For additional information please visit: http://www3.gehealthcare.com/en/products/categories/interventional_image_guided_systems/assist/flight_plan_for_liver

14. Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Iwazawa et al. European Journal of Radiology. 2013. Cornelis, F. H., Borgheresi, A., Petre, E., Santos, E., Solomon, S., & Brown, K. (2017)